Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients

Table 6 Association of quartiles of time-averaged markers of inflammation with mean ESA resistance index (ERI) over 6-month follow-up in maintenance hemodialysis patients

	Concentration	Model 1^a			Model 2^b			Model 3^c
	Concentration	β	95 % CI	P-value^d	β	95 % CI	P-value^d	β	95 % CI	P-value^d
hsCRP (mg/l)	<22.1	Reference	-	-	Reference	-	-	Reference	-	-
	22.1–<53.4	−1.15	−7.51, 5.21	0.72	3.09	−5.21, 11.4	0.47	4.27	−3.56, 12.1	0.29
	53.4–<117	2.29	−4.07, 8.64	0.48	4.76	−3.26, 12.8	0.25	4.65	−2.89, 12.2	0.23
	≥117	7.53	1.21, 13.8	0.02	11.2	3.41, 18.9	0.005	10.8	3.52, 18.1	0.004
IL-6 (pg/ml)	<9.4	Reference	-	-	Reference	-	-	Reference	-	-
	9.4–<14.1	2.01	−4.26, 8.28	0.53	2.29	−4.96, 9.54	0.54	2.30	−4.54, 9.14	0.51
	14.1–<20.8	6.39	0.11, 12.7	0.05	4.43	−2.88, 11.7	0.24	3.07	−3.86, 10.0	0.39
	≥20.8	10.7	4.42, 16.9	0.001	11.4	3.69, 19.0	0.004	10.2	2.98, 17.5	0.006

ERI defined as the weekly weight-adjusted ESA dose (units/kg/week) divided by the baseline hemoglobin level (g/dl)
ESA Erythropoeisis stimulating agent, hsCRP High-sensitivity C-reactive protein, IL-6 Interleukin-6
^a Unadjusted
^b Adjusted for age, sex, race, body mass index, etiology of end stage renal disease, diabetes status, transferrin saturation (serum iron/total iron binding capacity), Kt/V, serum parathyroid hormone, study visit, and treatment assignment
^c Adjusted for Model 2 covariates plus isofurans
^d P-values obtained from comparing regression coefficients to coefficient for lowest quartile of each inflammatory marker

ISSN: 1471-2369